Operating cash flow increased 15.6%
Operating cash flow changed +15.6% from the comparable as-filed period.
$39.8M→$46.0M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →ASAN financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Net income increased 19.0%
Net income changed +19.0% from the comparable as-filed period.
-$48.4M→-$39.2M2 prior comparisons
Total assets decreased 7.6%
Total assets changed -7.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$883.2M→$816.1M4 prior comparisons
Cash & equivalents increased 19.2%
Cash & equivalents changed +19.2% from the comparable as-filed period.
$184.1M→$219.6M2 prior comparisons
Revenue increased 9.9%
Revenue changed +9.9% from the comparable as-filed period.
$196.9M→$216.4M2 prior comparisons
Trade receivables increased 13.6%
Trade receivables changed +13.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
$69.2M→$78.6M4 prior comparisons
R&D / revenue moved 254 bp lower
R&D / revenue changed -254 basis points from the comparable as-filed period.
40.31%→37.76%2 prior comparisons
Stock-based compensation decreased 9.4%
Stock-based compensation changed -9.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$62.2M→$56.3M2 prior comparisons
Capex / revenue moved 3 bp higher
Capex / revenue changed +3 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
0.66%→0.69%2 prior comparisons
Capital expenditure increased 15.2%
Capital expenditure changed +15.2% from the comparable as-filed period.
$1.3M→$1.5M3 prior comparisons
Operating cash-flow margin moved 105 bp higher
Operating cash-flow margin changed +105 basis points from the comparable as-filed period.
20.23%→21.28%2 prior comparisons
Free-cash-flow margin moved 102 bp higher
Free-cash-flow margin changed +102 basis points from the comparable as-filed period.
19.57%→20.59%2 prior comparisons
Gross profit increased 5.3%
Gross profit changed +5.3% from the comparable as-filed period.
$176.7M→$186.1M2 prior comparisons
Receivables / revenue moved 118 bp higher
Receivables / revenue changed +118 basis points from the comparable as-filed period.
35.15%→36.34%2 prior comparisons
Research & development increased 3.0%
Research & development changed +3.0% from the comparable as-filed period.
$79.4M→$81.7M2 prior comparisons
Revenue increased 9.5%
Revenue changed +9.5% from the comparable as-filed period.
$187.3M→$205.1M3 prior comparisons
Capex / revenue moved 103 bp higher
Capex / revenue changed +103 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
0.34%→1.37%2 prior comparisons
Research & development decreased 12.0%
Research & development changed -12.0% from the comparable as-filed period.
$75.1M→$66.1M3 prior comparisons
Gross profit increased 6.9%
Gross profit changed +6.9% from the comparable as-filed period.
$168.0M→$179.7M3 prior comparisons
Cash & equivalents decreased 0.1%
Cash & equivalents changed -0.1% from the comparable as-filed period.
$193.8M→$193.7M2 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.